Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-08-28 Annual Report
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
FY2025 Full year results 6 pages 340.0KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 29 August 2025 presenting the FY2025 full-year financial results of 4DMedical Limited. It includes detailed financial performance data such as operating revenue, expenditure, cash balance, and growth metrics. It also discusses operational highlights, commercial contracts, FDA submission progress, and strategic partnerships. The document contains substantive financial data and analysis for the full fiscal year ended 30 June 2025, which aligns with the characteristics of an Annual Report or full-year financial results announcement. It is not merely an announcement of a report publication or a brief summary, but a comprehensive presentation of the company's yearly financial and operational performance. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2025-08-28 English
Application for quotation of securities - 4DX 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, issue price, and the class of securities. It is not a financial report, earnings release, or management discussion, but rather an official announcement related to capital changes and securities quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or certification.
2025-08-27 English
Notification regarding unquoted securities - 4DX 7 pages 22.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options by 4DMedical Limited. It includes specifics such as the number of securities issued, their exercise price, expiry date, and the purpose of the issue. The document is a formal notification to the ASX regarding the issuance of new securities, specifically unquoted options, and references compliance with ASX Listing Rules. There is no financial performance data, management discussion, or earnings information. The document is not an annual or interim report, nor is it a call transcript or governance report. It is a regulatory announcement about securities issuance. According to the filing definitions, this fits best under 'Share Issue/Capital Change (SHA)' which covers announcements regarding new share issues or capital changes. The document length (7473 characters) and content confirm it is the announcement itself, not a brief report publication notice or certification. Therefore, the classification is SHA with high confidence.
2025-08-27 English
Quarterly Activity Report and Appendix 4C 13 pages 988.5KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activity Report and Appendix 4C for Q4 FY2025' dated 31 July 2025. It contains detailed financial performance data for the quarter and full fiscal year, operational metrics, commercial updates, and strategic investment information. The presence of substantive financial data such as operating revenue, cash flows, and operational metrics confirms it is a comprehensive quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2025
2025-07-30 English
Proposed issue of securities - 4DX 5 pages 17.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement or other type of securities issue by 4DMedical Limited. It includes specifics such as the number of securities, issue date, consideration, and compliance with ASX Listing Rules. The content focuses on the announcement of a new securities issue rather than financial results or management commentary. It is a formal announcement related to capital raising activities, consistent with a Capital/Financing Update. The document length is over 6,000 characters and contains detailed information about the securities issue, not just a brief notice or reference to another report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-07-30 English
4DMedical secures $10m strategic investment from Pro Medicus 3 pages 233.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 31 July 2025 about 4DMedical securing a $10 million strategic investment from Pro Medicus. It details the terms of a secured facility agreement, including the structure of the investment as a hybrid debt and equity loan, use of proceeds, interest rate, maturity, security, repayment terms, and conditions precedent. The document also includes an investor webinar announcement and company background information. There are no financial statements or comprehensive financial performance data presented, nor is this a full annual or interim report. The content focuses on a financing transaction and capital structure update. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length (7268 characters) and detailed terms support this classification with high confidence.
2025-07-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.